BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - BioCryst Pharma (NASDAQ:BCRX)

Company Overview - BioCryst Pharmaceuticals, Inc. is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases [3] - The company has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases [3] Stock Compensation - The compensation committee of BioCryst's board of directors granted three newly-hired employees restricted stock units (RSUs) covering an aggregate of 30,700 shares of BioCryst common stock as inducements for employment [1] - The RSUs were granted as of November 3, 2025, and will vest in four equal annual installments beginning on the one-year anniversary of the grant date, subject to the new employee's continued service with the company [2] - The RSUs are subject to the terms and conditions of BioCryst's Inducement Equity Incentive Plan and a restricted stock unit agreement covering the grant [2]